HCM
PCRX icon

Highbridge Capital Management’s Pacira BioSciences PCRX Stock Holding History

Highbridge Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,000
Closed -$1.56M – 1231
2018
Q1 		$1.56M Sell
50,000
-100,000
-67% -$3.56M 0.03% 466
2017
Q4 		$6.85M Sell
150,000
-52,700
-26% -$2.09M 0.12% 213
2017
Q3 		$7.61M Buy
202,700
+8,618
+4% +$347K 0.11% 208
2017
Q2 		$9.26M Buy
194,082
+114,082
+143% +$5.29M 0.14% 184
2017
Q1 		$3.65M Buy
+80,000
New +$3.46M 0.05% 347
2016
Q4 		– Sell
-55,872
Closed -$1.91M – 1514
2016
Q3 		$1.91M Buy
+55,872
New +$2.19M 0.03% 439
2015
Q4 		– Sell
-35,691
Closed -$1.47M – 1724
2015
Q3 		$1.47M Buy
+35,691
New +$2.19M 0.02% 647

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return